22 JUNE 2018
Availability of Hiprex 1g Tablets
MEDA Pharmaceuticals Ltd, a Mylan company, the marketing authorisation holder for Hiprex in the UK; is currently experiencing a temporary supply constraint of Hiprex 1g tablets.
Latest Supply Status
We are experiencing a temporary supply constraint of Hiprex 1g tablets and anticipate normal stock levels to resume in due course. During this period, Hiprex 1g tablets may not be available.
With patient access our priority, we will continue to proactively and diligently provide updates on our website regarding any changes in stock availability.
Ongoing Supply Management
Mylan is working diligently to manage supply and expediting where possible to alleviate the situation and achieve a steady state of supply as expeditiously as possible.
Information for Patients and Prescribers
Mylan is unable to make any specific treatment recommendations to healthcare professionals or for individual patients, however, it is recommended that patients affected by this should speak to their healthcare professional to discuss treatment options according to their health needs and their relevant clinical history.
Hiprex is indicated in the prophylaxis and treatment of urinary tract infections.
If you require additional information or have any questions, please contact +44(0) 1707 853 100.
Job Code: HIP-2018-0002
Date of Preparation: June 2018